Anthem Biosciences Share News - Latest Updates, Live News & More

Latest news about Anthem Biosciences

Anthem Biosciences Q3FY26: Revenue ₹4,232 Mn with EBITDA Margin at 41.8% 2 hrs ago Today

Anthem Biosciences announced Q3FY26 results with revenue of ₹4,232 Mn and EBITDA margin at 41.8%, while nine-month revenue reached ₹15,134 Mn showing 11.2% growth. The company demonstrated strong margin expansion and operational efficiency despite quarterly revenue decline, with management expressing confidence in strong year-end performance.

Anthem Biosciences Schedules Q3FY26 Earnings Conference Call for February 05, 2026 8 days ago

Anthem Biosciences Issues ₹49 Crore Corporate Guarantee for Subsidiary's Working Capital Facility Jan 07, 2026

Anthem Biosciences Reports Insider Trading Code Violations by Two Designated Persons Nov 11, 2025

Anthem Biosciences Reports Revenue Growth but Profit Decline in Q2 FY2026 Nov 08, 2025

More news about Anthem Biosciences

28Oct 25

Anthem Biosciences Reports Code of Conduct Violation by Designated Person

Anthem Biosciences Limited has disclosed a violation of its Code of Conduct by a designated person who traded in company securities during a trading window closure period, contravening SEBI Prohibition of Insider Trading Regulations. The matter will be presented at the upcoming Audit Committee meeting, with the company committing to provide detailed disclosure and information about actions taken in due course. The disclosure was made in compliance with SEBI PIT Regulations and the company's internal Code of Conduct.

15Oct 25

Lock-in Periods End for Anthem BioSciences, Shringar House, and Dev Accelerator

Three companies - Anthem BioSciences, Shringar House of Mangalsutra, and Dev Accelerator - are set to see their share lock-in periods expire on October 15. This could increase the supply of tradable shares in the market. Anthem BioSciences will unlock 8.90 million shares (2% of equity), Shringar House of Mangalsutra 3.60 million shares (4% of equity), and Dev Accelerator 5.20 million shares (6% of equity). Since their IPOs, Anthem BioSciences is up 8%, Shringar House of Mangalsutra is trading near its listing price, and Dev Accelerator is down 21%. While the expiry makes these shares eligible for trading, it doesn't guarantee they will be sold in the open market.

16Sept 25

Anthem Biosciences Shares Surge 46% Post-Listing on Strong Q1 Performance and Expansion Plans

Anthem Biosciences' shares have risen 46% since its July 21 listing, with an additional 11% increase following robust June-quarter results. Q1 revenue grew 59.50% YoY to ₹540.20 crore, while net profit increased 64.80% to ₹135.80 crore. The company is expanding production capacity, aiming for 425 kilolitres by September 2025. Two new products were approved, expanding the commercial portfolio to 12. Anthem projects 20% annual revenue growth for FY26 and is developing GLP-1 drugs for obesity and diabetes.

18Aug 25

Anthem Biosciences Reports Strong Q1 FY26 Results with 60% Revenue Growth

Anthem Biosciences Limited reported robust Q1 FY26 results, with consolidated revenue reaching INR 540.00 crores, a 60% year-on-year growth. EBITDA stood at INR 214.30 crores with a 38% margin, while PAT was INR 135.80 crores with a 24% margin. The company added two commercial molecules and expanded its custom synthesis capacity. Anthem Biosciences maintains a strong pipeline with 8 molecules in Phase 3 trials and plans further capacity expansion across its units. The management expects to maintain historical growth rates of around 20% annually, despite this quarter's exceptional performance.

13Aug 25

Anthem Biosciences Reports Strong Q1 Results Amid Expansion Efforts

Anthem Biosciences, a leading CRDMO, reported robust Q1 financial results. Consolidated Revenue from Operations increased by 59.5% to ₹5,402.09 crore. EBITDA reached ₹2,143.00 crore with a 38% margin. PAT grew by 64.8% to ₹1,358.00 crore. The CRDMO segment contributed 83.8% of total revenue. The company is expanding its capabilities in API, intermediates, formulation, biologics, and specialty chemistry services. Operational expansions include new facilities at Unit II and Unit III in Harohalli, with construction beginning on a greenfield facility at Unit IV.

13Aug 25

Anthem Biosciences Reports Strong Q1 Results with 59.5% Revenue Growth

Anthem Biosciences, a leading CRDMO, announced robust Q1 FY24 results. Consolidated revenue increased by 59.5% to ₹5,402.09 million. EBITDA grew 52.7% to ₹2,143.00 million, with a 39.67% margin. PAT rose 64.8% to ₹1,357.91 million. The CRDMO segment saw 70.5% growth, while Specialty Ingredients grew 19.7%. The company completed capacity expansions, inaugurated new facilities, and maintained a strong net cash position of ₹7,848.00 million. Anthem recently completed its IPO and was listed on NSE and BSE.

22Jul 25

Anthem Biosciences Appoints Divya Prasad as Company Secretary and Compliance Officer

Anthem Biosciences Limited has appointed Ms. Divya Prasad as Company Secretary and Compliance Officer, effective October 18, 2024. Ms. Prasad, with ICSI Membership No: A41438, will also serve as Compliance Officer under SEBI regulations. The company has implemented various measures to ensure regulatory compliance, including appointing KFin Technologies Limited as Registrar & Share Transfer Agent and maintaining a structured digital database for unpublished price-sensitive information. A trading window closure has been announced from July 21, 2025, until 48 hours after the declaration of Q2 2025 financial results.

21Jul 25

Anthem Biosciences Shares Soar 27% on Stock Market Debut

Anthem Biosciences Limited made a strong market debut with shares opening at ₹723.05, a 27% premium over its IPO price of ₹570. This represents a gain of ₹153.05 per share for IPO investors. The impressive listing suggests investor confidence in the company's potential and reflects broader interest in the biosciences sector.